Assessing coverage and compliance of mass drug administration under elimination of lymphatic filariasis program in Yadgir District, Karnataka

Shetty, Anil; Santhuram, Anil Navale; Sj, Nareshkumar

doi:10.5455/ijmsph.2012.1.71-74

Cited by 6 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the reasons for the lower Mf clearance in this study might be due to the difficulty in ensuring that all the participants swallowed all the tablets provided to them during night hours in a village setting. Our study showed that compliance rates (IDA: 73.5% Vs DA: 82.9% of eligible village residents) were at least comparable with available independent coverage survey results in Yadgir with two drugs (90.1% and 75.4% of the eligible population) after 8 and 15 rounds of MDA in 2011 and 2018) and higher than that reported after 11 rounds of MDA in 2015 (56.2%) [14][15][16]. Indeed, many residents of our study villages reported never having swallowed MDA drugs prior to this study.…”

Section: Plos Neglected Tropical Diseasessupporting

confidence: 83%

“…The district has provided MDA for LF elimination since 2004, and 12 annual rounds of MDA with DA had been completed by 2016, prior to initiation of the present study. Independent coverage surveys conducted in Yadgir after 8, 11 and 15 rounds of MDA in 2011, 2015 and 2018 showed medication consumption rates of 90.1, 56.2 and 75.4% for the eligible population [14][15][16]. For the remaining rounds, no data were available.…”

Section: Study Locationmentioning

confidence: 99%

See 1 more Smart Citation

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India

et al. 2021

View full text Add to dashboard Cite

Background Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamazine and albendazole) or DA (diethylcarbamazine and albendazole) in India. Methodology/Principal findings This two-armed, open-labelled, block randomised, community study was conducted in LF endemic villages in Yadgir district, Karnataka, India. Consenting participants ≥5 years of age were tested for circulating filarial antigenemia (CFA) and microfilaremia (Mf) before treatment with a single oral dose of IDA or DA. Adverse events (AEs) were monitored actively for two days and passively for five more days. Persons with positive CFA or Mf tests at baseline were retested 12-months post-treatment to assess treatment efficacy. Baseline CFA and Mf—rates were 26.4% and 6.9% in IDA and 24.5% and 6.4% in DA villages respectively. 4758 and 4160 participants received IDA and DA. Most AEs were mild after both treatments; fewer than 0.1% of participants experienced AEs with severity > grade 1. No serious AEs were observed. Fever, headache and dizziness were the most common AEs. AE rates were slightly higher after IDA than DA (8.3% vs. 6.4%, P<0.01). AEs were more frequent in females and Mf-positives after either treatment, but significantly more frequent after IDA (40.5% vs 20.2%, P < 0.001). IDA was more effective for clearing Mf than DA (84% vs. 61.8%, P < 0.001). Geometric mean Mf counts per 60μl in retested Mf-positives decreased by 96.4% from 11.8 after IDA and by 90.0% from 9.5 after DA. Neither treatment was effective for clearing CFA. Conclusions/Significance IDA had an acceptable safety profile and was more effective for clearing Mf than DA. With adequate compliance and medical support to manage AEs, IDA has the potential to accelerate LF elimination in India. Trial registration Clinical Trial Registry of India (CTRI No/2016/10/007399)

show abstract

Section: Plos Neglected Tropical Diseasessupporting

confidence: 83%

Section: Study Locationmentioning

confidence: 99%

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India

et al. 2021

View full text Add to dashboard Cite

show abstract

“…72.3% thus showing an improvement in compliance rate compared to previous years. 12,13 The effective coverage rate in the present study was 76.89% in Kalaburagi district and 75.42% in Yadgir district, indicating an increased effective coverage in Yadgir district compared to the 2015 survey i.e. 56.17% and decreased effective coverage in Kalaburagi district i.e.…”

Section: Discussionmentioning

confidence: 49%

Evaluation of coverage and compliance to mass drug administration for lymphatic filariasis elimination in two endemic districts of Karnataka

Shivalingaiah

Ravikumar²,

Gurupadaswamy

2019

Int J Community Med Public Health

View full text Add to dashboard Cite

Background: Lymphatic filariasis is a debilitating and disfiguring disease causing significant socioeconomic burden. India is endemic for filariasis which includes Kalaburagi and Yadgir districts in Karnataka. India has the target for filariasis elimination by 2020 and mass drug administration [MDA] is a strategy for elimination. The objective of the study was to evaluate the coverage and compliance of mass drug administration against lymphatic filariasis.Methods: The study was a cross sectional study conducted during the month of October 2018 in Kalaburagi and Yadgir districts. The study subjects included all the residents of cluster except subjects aged below 2 years and pregnant women. Multi stage sampling was used and three clusters from rural area and one cluster from urban area from each district. Data collection was done by household survey after informed consent using a standard questionnaire.Results: A total population of 1,963 subjects residing in 399 houses of two districts was included. Majority of the study subjects 1517 (77.27%) were in the age group of more than 15 years with predominantly males 984(50.12%). The coverage rate and compliance rate of MDA was 83.17% and 92.46% in Kalaburagi district and 86.71% and 86.98% in Yadgir district respectively. The effective coverage rate and coverage compliance gap was 76.89% and 7.53% in Kalaburagi district, 75.42% and 13.01% in Yadgir district. Incomplete dose of MDA was consumed by 17 subjects in Kalaburagi district and 21 subjects in Yadgir district.Conclusions: The effective MDA coverage in both the study districts is below 85% which is not satisfactory.

show abstract

“…The compliance rates to the drugs distributed in the MDA campaign have generally been in the range of 46 to 93% in the endemic districts of Karnataka from the years 2007 to 2013 which may reflect on the need for strengthening of the BCC activities during MDA campaigns among the beneficiaries. [4][5][6][7][8][9][10][11] The MDA coverage rates in Gulbarga district has been inconsistent and reported as 32.7% in 2008, 38.8% in 2012 and 93.4% in 2014. 8,6,10 This inconsistent performance of the drug distribution in the MDA campaigns can explain to the continued LF transmission in this district.…”

Section: Discussionmentioning

confidence: 99%

“…[4][5][6][7][8][9][10][11] The MDA coverage rates in Gulbarga district has been inconsistent and reported as 32.7% in 2008, 38.8% in 2012 and 93.4% in 2014. 8,6,10 This inconsistent performance of the drug distribution in the MDA campaigns can explain to the continued LF transmission in this district. The microfilaria rate in Gulbarga district in 2015 is 0.7% compared to 0.45% at national level in 2014.…”

Section: Discussionmentioning

confidence: 99%

Programmatic evaluation of mass drug administration for elimination of lymphatic filariasis and reasons for non-compliance in Gulbarga district, Karnataka in 2015

Kumar¹,

Sunil²

2018

Int J Community Med Public Health

View full text Add to dashboard Cite

Background: Mass drug administration (MDA) to eliminate lymphatic filariasis (LF) is conducted once annually in the identified endemic districts of the country. MDA implementation is assessed by appointed independent teams within 2-3 weeks of the activity to suggest mid-term corrections and strengthen the on-going programme. This study was undertaken to assess the process of MDA implementation, drug coverage and compliance and to identify the reasons for non-compliance.Methods: A survey of four clusters comprising of three rural and one urban area was conducted in Gulbarga, during the third week following the MDA campaign in the district. Information pertaining to the MDA beneficiaries of the 124 evaluated households was collected over a period of three days using a structured proforma. The process of MDA implementation was evaluated at the district, taluk and primary health centre (PHC) levels.Results: From the information collected on 673 inmates of the households surveyed, the coverage and compliance rates of 87.5 and 60.9% respectively was found for diethylcarbamazine citrate and albendazole distribution and consumption. The important reasons for non–compliance to swallow the drugs identified were the beneficiaries being out of station during the campaign, was not aware of it, the drug distributer did not visit the beneficiaries house and fear of side effects of the drugs.Conclusions: Efforts to improve the compliance to consumption of the anti-filarial drugs at Gulbarga district is required for elimination of LF.

show abstract

Assessing coverage and compliance of mass drug administration under elimination of lymphatic filariasis program in Yadgir District, Karnataka

Cited by 6 publications

References 3 publications

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India

An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India

Evaluation of coverage and compliance to mass drug administration for lymphatic filariasis elimination in two endemic districts of Karnataka

Programmatic evaluation of mass drug administration for elimination of lymphatic filariasis and reasons for non-compliance in Gulbarga district, Karnataka in 2015

Contact Info

Product

Resources

About